How is the increasing complexity of modalities reshaping CDMO differentiation and specialization strategies?

Why CTMC CEO Jason Bock relishes the challenge of solving cell therapy’s most complex manufacturing and delivery problems Read the full article...

When every batch belongs to a single patient, a single centralized facility cannot serve the world. In Part 2, Chantale Bernatchez moves from...

The most underappreciated parameter in cell therapy process development is not your bioreactor, your media, or your activation protocol. It is the...